|US||Controlled in AL, AR, MS, GA|
Legal in all other states
|FDA Status||Not FDA Approved|
Etizolam is a benzodiazepine analog that possesses similar effects to prescription anxiolytics, such as alprazolam (Xanax), diazepam (Valium), clonazepam (Klonopin), and lorazepam (Ativan).
The drug is unscheduled an legal to purchase in most of the West.
Etizolam is not controlled at the federal level in the United States.
Etizolam is Schedule I in Alabama, Arkansas, and Mississippi.
It is Schedule IV in Georgia.
In all other states, etizolam is unscheduled and legal. Because benzodiazepines are typically Schedule IV, etizolam is not covered by the Federal Analogue Act, which only covers analogues of Schedule I and Schedule II substances.
Etizolam is unscheduled in the United Kingdom.
Etizolam is listed under Anlage III under German drug law.
Etizolam has a similar biological half life (6 hrs, 8 hrs) to alprazolam (Xanax) (11 hrs).
There is some evidence that etizolam has advantages over traditional benzodiazepines. When compared to alprazolam (Xanax), etizolam does not appear to build tolerance, and may even establish "reverse tolerance." In rat trials, etizolam was shown to actually cause an upregulation of benzodiazepine receptors, compared to lorazepam (Ativan), which caused downregulation (increased tolerance).
In a study that compared the effectiveness of etizolam, alprazolam, and bromazepam for the treatment of generalized anxiety disorder, all three drugs retained their effectiveness over 2 weeks, but etizolam became more effective from 2 weeks to 4 weeks, a type of reverse tolerance. Administering .5 mg etizolam twice daily did not induce cognitive deficits over 3 weeks when compared to placebo.